Elucidating the Potential of Bruton’s Tyrosine Kinase Inhibitors to Modulate Microglial Inflammation using Advanced 2D/3D Human Brain Cell Systems
Time: 8:00 am
day: Conference Day Two
Details:
- Evaluating the functional and pharmacological properties of Fenebrutinib in blocking BTK-mediated disease-associated activation in human microglia and complex brain cell systems
- Fenebrutinib treatment attenuated pathogenic neuroinflammation associated with FcyR activation while preserving homeostatic innate immune cell functions
- This study increases understanding of potential BTK functions in human microglial signalling and neuroinflammation relevant to MS pathogenesis